How many drugs treat Infective otitis media?

Drug Landscape tracks 10 marketed treatments for Infective otitis media (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/infective-otitis-media.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Infective otitis media — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infective otitis media (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Infective otitis media, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cedax	ceftibuten	Burke Therap	Cephalosporin Antibacterial		1995-01-01
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Biaxin	clarithromycin	Generic (originally Abbott/AbbVie)	Macrolide Antimicrobial [EPC]	Potassium voltage-gated channel subfamily H member 2	1991-10-31
Cefzil	cefprozil	Teva Pharmaceuticals USA	Cephalosporin Antibacterial [EPC]		1991-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Augmentin 250	CLAVULANIC ACID	Dr Reddys Labs Inc	beta Lactamase Inhibitor		1984-01-01
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Ciclacillin	CYCLACILLIN	Pfizer	cyclacillin		1979-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 11 drugs in Infective otitis media
Pfizer · 5 drugs in Infective otitis media
Bristol-Myers Squibb · 2 drugs in Infective otitis media
GSK · 2 drugs in Infective otitis media
Generic (originally Abbott/AbbVie) · 1 drug in Infective otitis media
Burke Therap · 1 drug in Infective otitis media
Assistance Publique - Hôpitaux de Paris · 1 drug in Infective otitis media
Dr Reddys Labs Sa · 1 drug in Infective otitis media
Bayer AG · 1 drug in Infective otitis media
Dr Reddys Labs Inc · 1 drug in Infective otitis media
Centre Hospitalier Universitaire Vaudois · 1 drug in Infective otitis media
Astellas Pharma · 1 drug in Infective otitis media

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Infective otitis media:

Cite this brief

Drug Landscape (2026). Infective otitis media — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infective-otitis-media. Accessed 2026-06-10.

Infective otitis media full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing